CareLit · DOI-Nachweis · Pneumologie
Use of nintedanib for the treatment of idiopathic pulmonary fibrosis: multi-centre real life experience in Germany
DOI 10.1055/s-0036-1572074
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Bonella, M Kreuter, L Hagmeyer, C Neurohr, K Milger, C Keller, M Kohlhäufl, J Müller-Quernheim, A Prasse
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease with a poor life expectancy. Nintedanib is a multiple tyrosine kinases inhibitor recently approved for the treatment of IPF, slowing disease progression by reducing the annual decline in lung function. Here we report the results of a large cohort of IPF patients who received nintedanib within a compassionate-use progra…
Zitieren
Zitierempfehlung
F Bonella, M Kreuter, L Hagmeyer, C Neurohr, K Milger, C Keller, M Kohlhäufl, J Müller-Quernheim, A Prasse (2016) Use of nintedanib for the treatment of idiopathic pulmonary fibrosis: multi-centre real life experience in Germany. Pneumologie (02). https://doi.org/10.1055/s-0036-1572074
Mit CareLit weiterarbeiten